Forecasting the cytokine storm following systematic interleukin (IL)-2 administration

Journal of Translational Medicine

Volumn 2, Issue , 2004, Pages

  Panelli, Monica C ^a   White, Richard ^b   Foster, Mareva ^b   Martin, Brian ^c   Wang, Ena ^a   Smith, Kina ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CHEMOATTRACTANT; CHEMOKINE; CILIARY NEUROTROPHIC FACTOR; COLLAGENASE 3; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; LEUKOCYTE MIGRATION INHIBITION FACTOR; LYMPHOTACTIN; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOKINE; RANTES; RECOMBINANT INTERLEUKIN 2; STROMAL CELL DERIVED FACTOR 1; STROMELYSIN; STROMELYSIN 2; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNINDEXED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL FUNCTION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BLOOD LEVEL; EFFECTOR CELL; FORECASTING; GENETIC TRANSCRIPTION; HUMAN; IMMUNOCOMPETENT CELL; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; METASTASIS; MICROENVIRONMENT; MONONUCLEAR PHAGOCYTE; PROTEIN MODIFICATION; T LYMPHOCYTE; THROMBOCYTOPENIA;

EID: 3242888623     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-2-17     Document Type: Article

References (34)

1. Margolin KA: Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000, 27:194-203.
2. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al.: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17:2105-2116.
3. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE.: Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4:321-327.
4. Cotran RS, Pober JS, Gimbrone Jr MA, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT.: Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 1988, 140:1883-1888.
5. Kasid A, Director EP, Rosenberg SA: Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol 1989, 143:736-739.
6. Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA.: Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986, 58:2764-2772.
7. White Jr RL, Schwartzentruber DJ, Guleria A, MacFarlane MP, White DE, Tucker E, Rosenberg SA: Cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994, 74:3212-3222.
8. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001, 19:3477-3482.
9. Papa MZ, Vetto JT, Ettinghausen SE, Mule JJ, Rosenberg SA: Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Res 1986, 46:5618-5623.
10. Fraker DL, Langstein HN, Norton JA: Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. J Exp Med 1989, 170:1015-1020.
11. Marincola FM: Interleukin-2. Biol Ther Cancer Updates 1994, 4(3):1-16.
12. Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA, Klein HG, Marincola FM: Genetic profiling of peripheral mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol 2002(7):RESEARCH0035.
13. Wang E, Miller L, Ohnmacht GA, Liu E, Marincola FM: High fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000, 18:457-459.
14. Masztalerz A, Van Rooijen N, Den Otter W, Everse LA: Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression. Cancer Immunol Immunother 2003, 52:235-242.
15. Panelli MC, Martin B, Nagorsen D, Wang E, Smith K, Monsurro' V, Marincola FM: A genomic and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. Cells Tissues Organs 788-T1 2004, in press.
16. Boccoli G, Masciulli R, Ruggeri EM, Carlini P, Giannella G, Montesoro E, Mastroberardino G, Isacchi G, Testa U, Calabresi F: Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res 1990, 50:5795-5800.
17. Deehan DJ, Heys SD, Simpson W, Herriot R, Broom J, Eremin O: Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2. Clin Exp Immunol 1994, 95:366-372.
18. List J, Moser RP, Steuer M, Loudon WG, Blacklock JB, Grimm EA: Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin-1 beta, interleukin-6, gamma-interferon and soluble interleukin-2 receptor (Mr 55,000 protein). Cancer Res 1992, 52:1123-1128.
19. Whittington R, Faulds D: Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993, 46:446-514.
20. Miller RG: Simultaneous statistical inference New York: Springer-Verlag 1981.
21. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998, 95:14863-14868.
22. Boratynska M: [Soluble cell adhesion molecules in chronic renal graft rejection]. Pol Arch Med Wewn 1998, 100:410-418.
23. Correale J, Bassani Molinas ML: Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol 2003, 140:198-209.
24. Zaccagni H, Fried J, Cornell J, Padilla P, Brey RL: Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage. Front Biosci 2004, 9:1654-1659.
25. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J: Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001, 104:1336-1342.
26. Hajilooi M, Sanati A, Ahmadieh A, Ghofraniha A, Massoud A: Circulating ICAM-1, VCAM-1, E-selectin, P-selectin, and TNFalphaRII in patients with coronary artery disease. Immunol Invest 2003, 32:245-257.
27. Holmlund A, Hulthe J, Millgard J, Sarabi M, Kahan T, Lind L: Soluble intercellular adhesion molecule-1 is related to endothelial vasodilatory function in healthy individuals. Atherosclerosis 2002, 165:271-276.
28. Lieuw-a-Fa M, Schalkwijk C, van Hinsbergh VW: Distinct accumulation patterns of soluble forms of E-selectin, VCAM-1 and ICAM-1 upon infusion of TNFalpha in tumor patients. Thromb Haemost 2003, 89:1052-1057.
29. Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, Cerundolo V, Anichini A: Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res 2000, 60:3559-3568.
30. Porter JF, Shen S, Denhardt DT: Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase. Br J Cancer 2004, 90:463-470.
31. Maury CP, Liljestrom M, Laiho K, Tiitinen S, Kaarela K, Hurme M: Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 2003, 48:3068-3076.
32. Jin P, Wang E: Polymorphism in clinical immunology. From HLA typing to immunogenetic profiling. J Transl Med 2003, 1:8.
33. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO: Systematic variation in gene expression patterns in human cancer cell lines. Nature Genetics 2000, 24:227-235.
34. Locker GJ, Kofler J, Stoiser B, Wilfing A, Wenzel C, Wogerbauer M, Steger GG, Zielinski CC, Mader R, Burgmann H: Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2. Eur Cytokine Netw 2000, 11(3):391-6.